Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › talazoparib

talazoparib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of talazoparib

22 trials tracked of talazoparib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 2142 citations.

22Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 10 Phase 1 8 Other / NA 3
  1. Phase 3 A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Completed · 2,142 cited
  2. Phase 2 Decitabine and Talazoparib in Untreated AML and R/R AML Completed
  3. Phase 2 A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Completed
  4. Phase 2 Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Completed
  5. Phase 2 Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes Completed
  6. Phase 2 Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma Completed
Show 16 more trials
  1. Phase 2 Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Completed
  2. Phase 2 Open-Label Extension and Safety Study of Talazoparib Completed
  3. Phase 2 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Completed
  4. Phase 2 Study of RP-3500, Camonsertib, in Advanced Solid Tumors Completed
  5. Phase 2 Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Completed
  6. Phase 1 An Open-Label Pharmacokinetics and Safety Study of Talazoparib Completed
  7. Phase 1 STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS Completed
  8. Phase 1 A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors Completed
  9. Phase 1 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
  10. Phase 1 A Study of Talazoparib in Patients With Advanced Solid Tumors Completed
  11. Phase 1 A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors Completed
  12. Phase 1 A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors Completed
  13. Phase 1 An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Completed
  14. N/A Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m Completed
  15. N/A Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed
  16. N/A Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
Oncology Phase I
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Apr 16, 2026
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
Oncology Phase II
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors.
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.
Apr 13, 2026